A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : RTX

Search Conditions:
Search Keyword : RTX
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: RTX
Appearance Frequency: 1596 time(s)
Long forms: 49

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
rituximab
(1000 times)
Rheumatology
(282 times)
RA (132 times)
AAV (53 times)
ANCA (53 times)
2002 Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
resiniferatoxin
(358 times)
Neurology
(104 times)
TRPV1 (84 times)
DRG (38 times)
CGRP (21 times)
1989 Duration of desensitization and ultrastructural changes in dorsal root ganglia in rats treated with resiniferatoxin, an ultrapotent capsaicin analog.
repeats-in-toxin
(112 times)
Biochemistry
(31 times)
LFA-1 (7 times)
ACT (4 times)
EHEC (4 times)
1994 Identification and immunological characterization of the domain of Actinobacillus actinomycetemcomitans leukotoxin that determines its specificity for human target cells.
raltitrexed
(39 times)
Neoplasms
(18 times)
TS (18 times)
5-FU (8 times)
FA (3 times)
1998 Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.
response to rituximab
(25 times)
Rheumatology
(15 times)
RA (14 times)
EULAR (7 times)
RF (5 times)
2008 NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.
response to treatment with rituximab
(5 times)
Rheumatology
(2 times)
DMTs (1 time)
EULAR (1 time)
FcgammaR (1 time)
2011 Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.
repeat toxin
(4 times)
Communicable Diseases
(2 times)
VSP (2 times)
1992 Separable domains define target cell specificities of an RTX hemolysin from Actinobacillus pleuropneumoniae.
received treatment with rituximab
(3 times)
Eye Diseases
(2 times)
AAR (1 time)
NMOSD (1 time)
2020 Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
Repeat-in-Toxins
(3 times)
Molecular Biology
(2 times)
--- 2012 Backbone resonance assignments of the outer membrane lipoprotein FrpD from Neisseria meningitidis.
10  repeats in the structural toxin
(3 times)
Veterinary Medicine
(2 times)
cDNA (1 time)
PCR (1 time)
2001 Cloning and characterization of a Moraxella bovis cytotoxin gene.
11  reported the efficacy of rituximab
(3 times)
Rheumatology
(2 times)
ANCA (1 time)
BVAS (1 time)
CRP (1 time)
2013 Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement.
12  re-treated with rituximab
(2 times)
Arthritis
(2 times)
AAV (1 time)
AZA (1 time)
CYC (1 time)
2013 Usefulness of power Doppler ultrasound for prediction of re-therapy with rituximab in rheumatoid arthritis: a prospective study of longstanding rheumatoid arthritis patients.
13  reported that rituximab
(2 times)
Allergy and Immunology
(2 times)
CAMR (1 time)
DeltaeGFR (1 time)
HC (1 time)
2008 Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
14  ruthenium tetroxide
(2 times)
Jurisprudence
(2 times)
CA (1 time)
2004 Evaluation of iodine-benzoflavone and ruthenium tetroxide spray reagents for the detection of latent fingermarks at the crime scene.
15  dose-rituximab
(1 time)
Hematology
(1 time)
AIHA (1 time)
NHL (1 time)
2012 Incipient Coombs' test negative autoimmune hemolytic anemia precedes non-Hodgkin's lymphoma.
16  RA treated with B-lymphocytedepletive rituximab
(1 time)
a-CCP (1 time)
a-MCV (1 time)
ACPA (1 time)
2010 Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.
17  randomized to receive either rituximab
(1 time)
Arthritis
(1 time)
AAV (1 time)
AZA (1 time)
CYC (1 time)
2014 Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
18  Rapid Thermal Exchange
(1 time)
Physical Fitness
(1 time)
HR (1 time)
Tc (1 time)
2009 Is performance of intermittent intense exercise enhanced by use of a commercial palm cooling device?
19  rapid thermal exchange device
(1 time)
Sports Medicine
(1 time)
HR (1 time)
WB (1 time)
WPV (1 time)
2010 Palm cooling does not reduce heat strain during exercise in a hot, dry environment.
20  Rapid Thermal Exchange System
(1 time)
Sports Medicine
(1 time)
HR (1 time)
RPE (1 time)
Tc (1 time)
2015 The effect of hand cooling during intermittent training of elite swimmers.
21  rats treated with resiniferatoxin
(1 time)
Medicine
(1 time)
HFD (1 time)
WAT (1 time)
2014 Capsaicin induces "brite" phenotype in differentiating 3T3-L1 preadipocytes.
22  real-world, long-term effectiveness of rituximab
(1 time)
Rheumatology
(1 time)
IS (1 time)
PFTs (1 time)
RA-ILD (1 time)
2020 Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease.
23  received the first rituximab
(1 time)
Urologic Diseases
(1 time)
ACEi (1 time)
2014 Immunoadsorption: a new strategy to induce remission in membranous lupus nephritis.
24  Recently the use of rituximab
(1 time)
Nephrology
(1 time)
MN (1 time)
PLA2R (1 time)
pts (1 time)
2020 Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
25  reduces the accessibility of rituximab
(1 time)
Clinical Laboratory Techniques
(1 time)
CNS (1 time)
MTX (1 time)
2010 Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system.
26  regarding the best rituximab
(1 time)
Nephrology
(1 time)
CR (1 time)
MCNS (1 time)
PSL (1 time)
2020 Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
27  related to resiniferatoxin
(1 time)
--- 2013 Resiniferatoxin for Pain Treatment: An Interventional Approach to Personalized Pain Medicine.
28  related to rituximab
(1 time)
Pharmacology
(1 time)
--- 2011 [Ulcerative colitis: exceptional consequence after rituximab therapy].
29  repeat treatment regimens of rituximab
(1 time)
Rheumatology
(1 time)
EULAR (1 time)
2010 Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
30  repeats in structural toxin genes
(1 time)
Allergy and Immunology
(1 time)
--- 2000 Legionella pneumophila entry gene rtxA is involved in virulence.
31  repeats in the toxin
(1 time)
Molecular Biology
(1 time)
CTX (1 time)
PCR (1 time)
TLC (1 time)
2014 Construction and characterization of a Vibrio cholerae serogroup O139 vaccine candidate by genetic engineering.
32  repeats-in-toxin domain
(1 time)
Allergy and Immunology
(1 time)
ACT (1 time)
wP (1 time)
2018 Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.
33  report two cases of rituximab
(1 time)
Medicine
(1 time)
--- 2015 [Rituximab-induced interstitial pneumonitis: report of two cases and literature review].
34  reporting the outcome of rituximab
(1 time)
Nephrology
(1 time)
FSGS (1 time)
MCD (1 time)
2014 Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
35  resistant to rituximab
(1 time)
Neoplasms
(1 time)
ALL (1 time)
ALM (1 time)
CDC (1 time)
2015 Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.
36  respond to conventional therapy, rituximab
(1 time)
Dermatology
(1 time)
MMP (1 time)
2012 Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.
37  response to raltitrexed
(1 time)
Neoplasms
(1 time)
DPD (1 time)
TP (1 time)
TS (1 time)
2003 Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
38  Response to Unilateral Periganglionic Resiniferatoxin
(1 time)
Pain
(1 time)
--- 2020 Response to "Unilateral Periganglionic Resiniferatoxin (RTX) for Personalized Pain Treatment".
39  responsiveness to rituximab
(1 time)
Rheumatology
(1 time)
RA (1 time)
TBG (1 time)
2020 Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα.
40  revealed that robustoxin
(1 time)
Toxicology
(1 time)
TTX-R (1 time)
TTX-S (1 time)
VTX (1 time)
1996 Selective alteration of sodium channel gating by Australian funnel-web spider toxins.
41  reverse transcription xenopolymerase
(1 time)
Science
(1 time)
RT (1 time)
2016 Synthetic evolutionary origin of a proofreading reverse transcriptase.
42  right ventricular Tei index
(1 time)
Veterinary Medicine
(1 time)
CVs (1 time)
ICCs (1 time)
RTXDPD (1 time)
2016 Repeatability and reproducibility of right ventricular Tei index valves derived from three echocardiographic methods for evaluation of cardiac function in dogs.
43  rituximab treatment
(1 time)
Allergy and Immunology
(1 time)
IGHV (1 time)
pSS (1 time)
2014 Ig gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjogren's syndrome patients.
44  Robotic thymectomy via the subxiphoid approach
(1 time)
Cardiology
(1 time)
--- 2020 The robotic thymectomy via the subxiphoid approach: technique and early outcomes.
45  RTX group
(1 time)
Otolaryngology
(1 time)
ANCA (1 time)
GC (1 time)
IVCY (1 time)
2018 The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis.
46  RTX test
(1 time)
Natural Science Disciplines
(1 time)
i.c.v (1 time)
TRPV1 (1 time)
2017 Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin.
47  RTX was acutely applied to the pericardial space in controls
(1 time)
Physiology
(1 time)
CHF (1 time)
FC (1 time)
MI (1 time)
2020 Cardiac sensory afferents modulate susceptibility to anxio-depressive behaviour in a mouse model of chronic heart failure.
48  RTX-5MS
(1 time)
Chemistry Techniques, Analytical
(1 time)
PCDDs (1 time)
PCDFs (1 time)
2001 Liquid crystalline polysiloxane polymer as stationary phase in gas chromatography capillary column for the separation of dioxin/furan compounds.
49  RTX/GO
(1 time)
Neoplasms
(1 time)
Ab (1 time)
GO (1 time)
NHL (1 time)
2016 Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.